HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association (“EHA”) Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.

The rest is here:
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

Erasca Announces Pricing of Underwritten Offering of Common Stock

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at a price of $1.85 per share. All of the shares to be sold in the offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $160 million. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 12,972,972 shares of common stock at the offering price. The offering is expected to close on May 21, 2024, subject to the satisfaction of customary closing conditions.

More here:
Erasca Announces Pricing of Underwritten Offering of Common Stock

QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency

STOCKHOLM, Sweden, May 17, 2024 (GLOBE NEWSWIRE) -- QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality Control Laboratories issued by the Swedish Medical Products Agency (Läkemedelsverket). QuTEM is thereby authorized to perform critical quality control analysis essential for the release of medicines to the market. The GMP Certificates and Manufacturing Permits cover medicinal and investigational medicinal products for both human and veterinary use.

See the original post here:
QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency

Dr. Douglas Fauser of Somers Orthopaedic Surgery & Sports Medicine Group Conducts First Autologous Live Stem … – PR Newswire

CARMEL, N.Y., May 15, 2024 /PRNewswire/ -- Dr. Douglas J. Fauser, a prominent sports medicine and total joint replacement specialist of the Somers Orthopaedic Surgery & Sports Medicine Group, along with Dr. Michael Baroody, a Board-Certified Plastic Surgeon, have achieved a groundbreaking milestone in orthopaedic medicine the first of its kind performed at the Orthopaedic & Spine Surgery Center (OSSC). On April 22, they successfully performed the first autologous live stem cell knee injection using cutting-edge technology. This revolutionary procedure, conducted under general anesthesia, involved the administration of purified concentrated live stem cells derived from the patient's own abdominal fat.

Dr. Fauser, who has dedicated over 30 years to delivering high-quality and cost-effective surgical solutions, is leading the way in non-operative treatments for osteoarthritis. The use of autologous stem cells represents a significant advancement in medical treatments, providing patients with an aggressive yet non-surgical option to manage the debilitating effects of osteoarthritis in knees.

"We are on the brink of a major shift in how we treat osteoarthritis," stated Dr. Fauser. "This first-of-its-kind procedure at OSSC utilizes autologous live stem cells, derived from the patient's own body, to potentially revolutionize the management of joint degeneration. Our goal is not just to alleviate symptoms but to target the underlying causes of osteoarthritis, offering patients a promising new pathway to recovery without surgery."

Fat tissue, which is known for its cushioning and supportive roles, contains a high concentration of reparative cells that may enhance the healing process. The innovative use of microfragmented adipose tissue, processed by the LIPOGEMS device, exemplifies the potential of fat to play a critical role in orthopaedic and arthroscopic surgeries.

The procedure underscores the advantages of using adipose tissue in orthopaedics, including its minimal invasiveness, abundance, and superior quality compared to other similar tissues. Research, supported by over 160 peer-reviewed publications, confirms the efficacy and safety of using microfragmented fat in various body areas including shoulders, knees, hips, and feet.

This pioneering treatment by Drs. Fauser and Baroody at OSSC not only paves the way for future advancements in orthopaedic medicine but also reinforces the center's commitment to providing innovative care that adheres to the highest standards of excellence. The Orthopedic & Specialty Surgery is a leading multi-specialty surgical facility, located at Somers Orthopaedic Surgery & Sports Medicine Group's Danbury location, providing outstanding surgical and patient care for a wide range of musculoskeletal conditions.

About Somers Orthopaedic Surgery & Sports Medicine Group

Founded in 1988, the group has been at the forefront of diagnosing and treating musculoskeletal conditions. It is staffed by board-certified physicians specializing in various orthopaedic disciplines. For more details, visit somersortho.com.

SOURCE Somers Orthopaedic Surgery & Sports Medicine Group

See the rest here:
Dr. Douglas Fauser of Somers Orthopaedic Surgery & Sports Medicine Group Conducts First Autologous Live Stem ... - PR Newswire

59-year-old Man Who Had Type 2 Diabetes for 25 Years is Cured by Stem Cells – Good News Network

Regular insulin and a syringe from ampoules and vials of medicines

Stem cells are being used more and more widely in treatments across the spectrum of medicine, but a recent breakthrough from Shanghai promises the best may still be yet to come.

A senior who had suffered from type-2 diabetes for 25 years hasnt taken insulin for 33 months after he received a regenerative islet cell transplantation.

Diabetes, particularly type 2the form that can develop in ones life because of poor diet and lifestyle choicesis one of the most prevalent non-communicable diseases on Earth.

China in particular is one of the worlds diabetes hotspots, with 140 million people unable to make their own insulin, and so suffer from kidney problems, blindness, amputation, and cardiovascular problems.

But this new breakthrough, coming after 10 years of research and testing, may change this paradigm of sickness forever.

Yin Hao, a leading researcher on the team and director of Shanghai Changzheng Hospitals Organ Transplant Center, said they took the patients own peripheral blood mononuclear cells and used existing methods to reprogram them back into pluripotent stem cells for injection into the pancreas.

Our technology has matured and it has pushed boundaries in the field of regenerative medicine for the treatment of diabetes, Yin, told China Daily whose team conducted the research with scientists from the Center for Molecular Cell Science at the Chinese Academy of Sciences.

Existing transplant treatments for type-2 diabetes are hindered by a lack of donor cells, and the complexity of pancreatic islet cell isolation technology.

ALSO CHECK OUT: Worlds First Tooth Regrowth Medicine Moves Toward Clinical Trials in Japan

Pancreatic islet cells are the major insulin-producing cells in the body, and the patients were almost completely inhibited. He relied on multiple insulin injections daily in addition to a kidney transplant.

After receiving the manufactured stem cells in 2021, he was weened off of external insulin over 11 weeks, after which his disease seemed to be largely gone.

MORE GOOD NEWS FOR DIABETES SUFFERERS: Crazy Insulin Prices Now a Thing of the Past in U.S. After Government Initiates Monthly Cost of $35

Follow-up examinations showed that the patients pancreatic islet function was effectively restored, and his renal function was within normal range, Yin said. Such results suggested that the treatment can avoid the progression of diabetic complications.

The paper was published in Cell Discovery on April 30th, and future studies, the authors wrote, should explore the pharmacology of drugs that might provide off-the-shelf equivalents for islet transplantation.

SHARE This Miracle Of Modern Medicine With Someone You Know With Diabetes

Original post:
59-year-old Man Who Had Type 2 Diabetes for 25 Years is Cured by Stem Cells - Good News Network

Hematopoietic Stem Cell Transplantation Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and … – openPR

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hematopoietic Stem Cell Transplantation pipeline constitutes 20+ key companies continuously working towards developing 20+ Hematopoietic Stem Cell Transplantation treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Hematopoietic Stem Cell Transplantation Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hematopoietic Stem Cell Transplantation Market.

The Hematopoietic Stem Cell Transplantation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hematopoietic Stem Cell Transplantation Pipeline Report: https://www.delveinsight.com/sample-request/hematopoietic-stem-cell-transplantation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Companies across the globe are diligently working toward developing novel Hematopoietic Stem Cell Transplantation treatment therapies with a considerable amount of success over the years. Hematopoietic Stem Cell Transplantation companies working in the treatment market are Orchard Therapeutics, Lisata Therapeutics, Genenta science, Editas Medicine, Talaris Therapeutics, Inc., and others, are developing therapies for the Hematopoietic Stem Cell Transplantation treatment Emerging Hematopoietic Stem Cell Transplantation therapies in the different phases of clinical trials are- OTL-204, OTL-105, LSTA201, Temferon, EDIT-301, LSTA12, FCR-001, and others are expected to have a significant impact on the Hematopoietic Stem Cell Transplantation market in the coming years. In May 2022, In order to begin a Phase 2b/3 research using mocravimod in acute myeloid leukaemia (AML) patients undergoing allogeneic hematopoietic stem cell transplant (HSCT), Priothera received approval from the US Food and Drug Administration (FDA). In December 2021, the United States Food and Drug Administration approved the treatment to prevent acute graft-versus-host disease (GVHD) in patients of 2 years of age or older receiving a hematopoietic stem cell transplant from a matched or single-HLA-mismatched unrelated donor.

Hematopoietic Stem Cell Transplantation Overview Hematopoietic stem cell transplant (HPSCT), also known as a bone marrow transplant, involves giving patients who have malfunctioning or depleted bone marrow viable hematopoietic stem cells. Clinical HPSCT comes in a variety of forms, and the transplanted cells might come from many sources.

Get a Free Sample PDF Report to know more about Hematopoietic Stem Cell Transplantation Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/hematopoietic-stem-cell-transplantation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Hematopoietic Stem Cell Transplantation Drugs Under Different Phases of Clinical Development Include: OTL-204: Orchard Therapeutics OTL-105: Orchard Therapeutics LSTA201: Lisata Therapeutics Temferon: Genenta science EDIT-301: Editas Medicine LSTA12: Lisata Therapeutics FCR-001: Talaris Therapeutics, Inc.

Hematopoietic Stem Cell Transplantation Route of Administration Hematopoietic Stem Cell Transplantation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Intravenous

Hematopoietic Stem Cell Transplantation Molecule Type Hematopoietic Stem Cell Transplantation Products have been categorized under various Molecule types, such as Peptide Protein Propylene glycols Cell Therapy

Hematopoietic Stem Cell Transplantation Pipeline Therapeutics Assessment Hematopoietic Stem Cell Transplantation Assessment by Product Type Hematopoietic Stem Cell Transplantation By Stage and Product Type Hematopoietic Stem Cell Transplantation Assessment by Route of Administration Hematopoietic Stem Cell Transplantation By Stage and Route of Administration Hematopoietic Stem Cell Transplantation Assessment by Molecule Type Hematopoietic Stem Cell Transplantation by Stage and Molecule Type

DelveInsight's Hematopoietic Stem Cell Transplantation Report covers around 20+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration

Further Hematopoietic Stem Cell Transplantation product details are provided in the report. Download the Hematopoietic Stem Cell Transplantation pipeline report to learn more about the emerging Hematopoietic Stem Cell Transplantation therapies https://www.delveinsight.com/sample-request/hematopoietic-stem-cell-transplantation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Hematopoietic Stem Cell Transplantation Therapeutics Market include: Key companies developing therapies for Hematopoietic Stem Cell Transplantation are - STEMCELL Technologies, Inc., Pluristem Therapeutics, Inc., Merck KGaA, ScienCell Research Laboratories, Inc., Lonza Group, and others.

Hematopoietic Stem Cell Transplantation Pipeline Analysis: The Hematopoietic Stem Cell Transplantation pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Hematopoietic Stem Cell Transplantation with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hematopoietic Stem Cell Transplantation Treatment. Hematopoietic Stem Cell Transplantation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Hematopoietic Stem Cell Transplantation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hematopoietic Stem Cell Transplantation market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hematopoietic Stem Cell Transplantation drugs and therapies https://www.delveinsight.com/sample-request/hematopoietic-stem-cell-transplantation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hematopoietic Stem Cell Transplantation Pipeline Market Drivers The Rise in the prevalence of Malignant Diseases, increasing Research and Developmental Activities are some of the important factors that are fueling the Hematopoietic Stem Cell Transplantation Market.

Hematopoietic Stem Cell Transplantation Pipeline Market Barriers However, lack of Knowledge and Risks Associated, post-HSCT Complications and other factors are creating obstacles in the Hematopoietic Stem Cell Transplantation Market growth.

Scope of Hematopoietic Stem Cell Transplantation Pipeline Drug Insight Coverage: Global Key Hematopoietic Stem Cell Transplantation Companies: Orchard Therapeutics, Lisata Therapeutics, Genenta science, Editas Medicine, Talaris Therapeutics, Inc., and others Key Hematopoietic Stem Cell Transplantation Therapies: OTL-204, OTL-105, LSTA201, Temferon, EDIT-301, LSTA12, FCR-001, and others Hematopoietic Stem Cell Transplantation Therapeutic Assessment: Hematopoietic Stem Cell Transplantation current marketed and Hematopoietic Stem Cell Transplantation emerging therapies Hematopoietic Stem Cell Transplantation Market Dynamics: Hematopoietic Stem Cell Transplantation market drivers and Hematopoietic Stem Cell Transplantation market barriers

Request for Sample PDF Report for Hematopoietic Stem Cell Transplantation Pipeline Assessment and clinical trials https://www.delveinsight.com/sample-request/hematopoietic-stem-cell-transplantation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents 1. Hematopoietic Stem Cell Transplantation Report Introduction 2. Hematopoietic Stem Cell Transplantation Executive Summary 3. Hematopoietic Stem Cell Transplantation Overview 4. Hematopoietic Stem Cell Transplantation- Analytical Perspective In-depth Commercial Assessment 5. Hematopoietic Stem Cell Transplantation Pipeline Therapeutics 6. Hematopoietic Stem Cell Transplantation Late Stage Products (Phase II/III) 7. Hematopoietic Stem Cell Transplantation Mid Stage Products (Phase II) 8. Hematopoietic Stem Cell Transplantation Early Stage Products (Phase I) 9. Hematopoietic Stem Cell Transplantation Preclinical Stage Products 10. Hematopoietic Stem Cell Transplantation Therapeutics Assessment 11. Hematopoietic Stem Cell Transplantation Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Hematopoietic Stem Cell Transplantation Key Companies 14. Hematopoietic Stem Cell Transplantation Key Products 15. Hematopoietic Stem Cell Transplantation Unmet Needs 16 . Hematopoietic Stem Cell Transplantation Market Drivers and Barriers 17. Hematopoietic Stem Cell Transplantation Future Perspectives and Conclusion 18. Hematopoietic Stem Cell Transplantation Analyst Views 19. Appendix 20. About DelveInsight

Related Reports:

Hematopoietic Stem Cell Transplantation Market https://www.delveinsight.com/report-store/hematopoietic-stem-cell-transplantation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Hematopoietic Stem Cell Transplantation Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Hematopoietic Stem Cell Transplantation Epidemiology https://www.delveinsight.com/report-store/hematopoietic-stem-cell-transplantation-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Hematopoietic Stem Cell Transplantation Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Aneurysmal Subarachnoid Hemorrhage Market https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Excerpt from:
Hematopoietic Stem Cell Transplantation Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and ... - openPR

Challenges and perspectives of heart repair with pluripotent stem cell-derived cardiomyocytes – Nature.com

Nabel, E. G. & Braunwald, E. A tale of coronary artery disease and myocardial infarction. N. Engl. J. Med. 366, 5463 (2012).

Article CAS PubMed Google Scholar

McDonagh, T. A. et al. Group ESCSD. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 35993726 (2021).

Article CAS PubMed Google Scholar

Goldenberg, B. Ueber Atrophie und Hypertrophie der Muskelfasern des Herzens. Arch. Pathol. Anat. Physiol. Klin. Med. 103, 88130 (1886).

Article Google Scholar

Linzbach, A. J. Heart failure from the point of view of quantitative anatomy. Am. J. Cardiol. 5, 370382 (1960).

Article CAS PubMed Google Scholar

Linzbach, A. J. Hypertrophy, hyperplasia and structural dilatation of the human heart. Adv. Cardiol. 18, 114 (1976).

Article CAS PubMed Google Scholar

Soonpaa, M. H., Kim, K. K., Pajak, L., Franklin, M. & Field, L. J. Cardiomyocyte DNA synthesis and binucleation during murine development. Am. J. Physiol. 271, H2183H2189 (1996).

CAS PubMed Google Scholar

Bergmann, O. et al. Evidence for cardiomyocyte renewal in humans. Science 324, 98102 (2009).

Article CAS PubMed PubMed Central Google Scholar

Olivetti, G. et al. Apoptosis in the failing human heart. N. Engl. J. Med. 336, 11311141 (1997).

Article CAS PubMed Google Scholar

Quaini, F. et al. Chimerism of the transplanted heart. N. Engl. J. Med. 346, 515 (2002).

Article PubMed Google Scholar

Orlic, D. et al. Bone marrow cells regenerate infarcted myocardium. Nature 410, 701705 (2001).

Article CAS PubMed Google Scholar

Jeyaraman, M. M. et al. Autologous bone marrow stem cell therapy in patients with st-elevation myocardial infarction: a systematic review and meta-analysis. Can. J. Cardiol. 33, 16111623 (2017).

Article PubMed Google Scholar

Blau, H. M., Brazelton, T. R. & Weimann, J. M. The evolving concept of a stem cell: entity or function? Cell 105, 829841 (2001).

Article CAS PubMed Google Scholar

Dimmeler, S., Zeiher, A. M. & Schneider, M. D. Unchain my heart: the scientific foundations of cardiac repair. J. Clin. Invest. 115, 572583 (2005).

Article CAS PubMed PubMed Central Google Scholar

Beltrami, A. P. et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114, 763776 (2003).

Article CAS PubMed Google Scholar

Oh, H. et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc. Natl Acad. Sci. USA 100, 1231312318 (2003).

Article CAS PubMed PubMed Central Google Scholar

Laugwitz, K. L. et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature. 433, 647653 (2005).

Article CAS PubMed PubMed Central Google Scholar

Planat-Benard, V. et al. Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ. Res. 94, 223229 (2004).

Article CAS PubMed Google Scholar

Condorelli, G. et al. Cardiomyocytes induce endothelial cells to trans-differentiate into cardiac muscle: Implications for myocardium regeneration. Proc. Natl Acad. Sci. USA 98, 1073310738 (2001).

Article CAS PubMed PubMed Central Google Scholar

Li, Y. et al. Genetic lineage tracing of nonmyocyte population by dual recombinases. Circulation 138, 793805 (2018).

Article CAS PubMed Google Scholar

Murry, C. E. et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428, 664668 (2004).

Article CAS PubMed Google Scholar

Nygren, J. M. et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat. Med. 10, 494501 (2004).

Article CAS PubMed Google Scholar

Laflamme, M. A., Myerson, D., Saffitz, J. E. & Murry, C. E. Evidence for cardiomyocyte repopulation by extracardiac progenitors in transplanted human hearts. Circ. Res. 90, 634640 (2002).

Article CAS PubMed Google Scholar

Hocht-Zeisberg, E. et al. Cellular repopulation of myocardial infarction in patients with sex-mismatched heart transplantation. Eur. Heart J. 25, 749758 (2004).

Article PubMed Google Scholar

Partners HealthCare and Brigham and Womens Hospital agree to pay $10 million to resolve research fraud allegations. US Attorneys Office District of Massachusetts https://www.justice.gov/usao-ma/pr/partners-healthcare-and-brigham-and-women-s-hospital-agree-pay-10-million-resolve (2017).

Eschenhagen, T. et al. Cardiomyocyte regeneration: a consensus statement. Circulation 136, 680686 (2017).

Article PubMed PubMed Central Google Scholar

Senyo, S. E. et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature 493, 433436 (2013).

Article CAS PubMed Google Scholar

Vagnozzi, R. J. et al. An acute immune response underlies the benefit of cardiac stem cell therapy. Nature 577, 405409 (2020).

Article CAS PubMed Google Scholar

Sadek, H. & Olson, E. N. Toward the goal of human heart regeneration. Cell Stem Cell 26, 716 (2020).

Article CAS PubMed PubMed Central Google Scholar

Giacca, M. Fulfilling the promise of rna therapies for cardiac repair and regeneration. Stem Cells Transl. Med. 12, 527535 (2023).

Article PubMed PubMed Central Google Scholar

Yamada, Y., Sadahiro, T. & Ieda, M. Development of direct cardiac reprogramming for clinical applications. J. Mol. Cell Cardiol. 178, 18 (2023).

Article CAS PubMed Google Scholar

Soonpaa, M. H., Koh, G. Y., Klug, M. G. & Field, L. J. Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium. Science 264, 98101 (1994).

Article CAS PubMed Google Scholar

Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 11451147 (1998).

Article CAS PubMed Google Scholar

Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861872 (2007).

Article CAS PubMed Google Scholar

Kehat, I. et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J. Clin. Invest. 108, 407414 (2001).

Article CAS PubMed PubMed Central Google Scholar

Kattman, S. J. et al. Stage-specific optimization of activin/nodal and bmp signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell. 8, 228240 (2011).

Article CAS PubMed Google Scholar

Burridge, P. W. & Zambidis, E. T. Highly efficient directed differentiation of human induced pluripotent stem cells into cardiomyocytes. Methods Mol. Biol. 997, 149161 (2013).

Article CAS PubMed Google Scholar

Breckwoldt, K. et al. Differentiation of cardiomyocytes and generation of human engineered heart tissue. Nat. Protoc. 12, 11771197 (2017).

Article CAS PubMed Google Scholar

Halloin, C., Coffee, M., Manstein, F. & Zweigerdt, R. Production of cardiomyocytes from human pluripotent stem cells by bioreactor technologies. Methods Mol. Biol. 1994, 5570 (2019).

Article CAS PubMed Google Scholar

Buikema, J. W. et al. Wnt activation and reduced cellcell contact synergistically induce massive expansion of functional human iPSC-derived cardiomyocytes. Cell Stem Cell 27, 5063 (2020).

Article CAS PubMed PubMed Central Google Scholar

Eschenhagen, T., Ridders, K. & Weinberger, F. How to repair a broken heart with pluripotent stem cell-derived cardiomyocytes. J Mol Cell Cardiol. 163, 106117 (2022).

Article CAS PubMed Google Scholar

Weinberger, F. & Eschenhagen, T. Cardiac regeneration: new hope for an old dream. Annu. Rev. Physiol. 83, 5981 (2021).

Article CAS PubMed Google Scholar

Shiba, Y. et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature 538, 388391 (2016).

Article CAS PubMed Google Scholar

Chong, J. J. et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510, 273277 (2014).

Article CAS PubMed PubMed Central Google Scholar

Liu, Y. W. et al. Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates. Nat. Biotechnol. 36, 597605 (2018).

Article CAS PubMed PubMed Central Google Scholar

Querdel, E. et al. Human engineered heart tissue patches remuscularize the injured heart in a dose-dependent manner. Circulation 143, 19912006 (2021).

Article CAS PubMed PubMed Central Google Scholar

Riegler, J. et al. Human engineered heart muscles engraft and survive long term in a rodent myocardial infarction model. Circ. Res. 117, 720730 (2015).

Article CAS PubMed PubMed Central Google Scholar

Laflamme, M. A. et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 25, 10151024 (2007).

Article CAS PubMed Google Scholar

Weinberger, F. et al. Cardiac repair in guinea pigs with human engineered heart tissue from induced pluripotent stem cells. Sci. Transl. Med. 8, 363ra148 (2016).

Article PubMed Google Scholar

Bergmann, O. et al. Dynamics of cell generation and turnover in the human heart. Cell 161, 15661575 (2015).

Article CAS PubMed Google Scholar

Lou, X. et al. N-cadherin overexpression enhances the reparative potency of human-induced pluripotent stem cell-derived cardiac myocytes in infarcted mouse hearts. Cardiovasc. Res. 116, 671685 (2020).

Article CAS PubMed Google Scholar

Kobayashi, H. et al. Intracoronary transplantation of pluripotent stem cell-derived cardiomyocytes: inefficient procedure for cardiac regeneration. J. Mol. Cell Cardiol. 174, 7787 (2023).

Here is the original post:
Challenges and perspectives of heart repair with pluripotent stem cell-derived cardiomyocytes - Nature.com

After 3,000 years of science, the embryo is very different – Aeon

Fifty-four years ago, I did something extraordinary. I built myself. I was a single, round cell with not the slightest hint of my final form. Yet the shape of my body now the same body is dazzlingly complex. I am comprised of trillions of cells. And hundreds of different kinds of cells; I have brain cells, muscle cells, kidney cells. I have hair follicles, though tragically few still decorate my head.

But there was a time when I was just one cell. And so were you. And so were my cats, Samson and Big Mitch. That salmon I had for dinner last night and the last mosquito that bit you also started as a single cell. So did Tyrannosaurus rex and so do California redwoods. No matter how simple or complex, every organism starts as a single cell. And from that humble origin emerges what Charles Darwin called endless forms most beautiful.

Once youve come to terms with that mind-boggling fact, consider this: all organisms, including humans, build themselves. Our construction proceeds with no architects, no contractors, no builders; it is our own cells that build our bodies. Watching an embryo, then, is rather like watching a pile of bricks somehow make themselves into a house, to paraphrase the biologist Jamie Davies in Life Unfolding (2014).

This process of body sculpting is called embryonic development, and it is a symphony of cells and tissues conducted by genetics, biochemistry and mechanics. People who study this, like me, are called developmental biologists. And while you may not know it, our field is in a period of tremendous excitement, but also upheaval.

In the summer of 2022, I sat in the back of a lecture hall in Santa Cruz, California listening to a lecture from Magdalena ernicka-Goetz, professor of mammalian development and stem cell biology at the University of Cambridge, UK. She is a controversial figure and one of many scientists trying to push the limits of understanding human embryos. I heard, too, from Ruth Lehmann, director of MITs prestigious Whitehead Institute for Biomedical Research. Shed been in the news for firing a famous scientist for sexual harassment, but whats made her an international leader in biology for decades is her brilliant and creative study of developmental biology, in fruit flies.

This juxtaposition of fly and human embryos wasnt surprising; developmental biology is propelled by a whole zoo of embryos fruit flies, yes, but also sea urchins, worms, frogs, mice. Indeed, our great triumph in the 20th century was revealing the astonishing molecular similarity of all embryos; and, for precisely that reason, studies of animal embryos have garnered seven Nobel Prizes in the past 30 years alone. What surprised me in Santa Cruz was just how fast our collective understanding of animal embryos is making possible truly explosive advances in human embryology. So, while Lehmanns fascinating new work on cell migration in fly embryos kept the audience rapt, it was ernicka-Goetz who caught the medias attention.

Developmental biology is something society needs to understand. And dont we want to?

Together with Jacob Hannas lab in Israel, ernicka-Goetz was building what scientists call embryo models. These biological entities look a lot like embryos; they start as relatively few cells and few cell types, and they grow and elaborate over time. But theyre not made in the usual way. Eschewing both egg and sperm, embryo models are created by manipulating embryonic stem cells. Perhaps best known to the public for their promised miracle cures or as proxies for abortion debates, these cells display a remarkable power. They can be made to differentiate into essentially any cell type in the body. Now, it seems, we might even use them to make embryos.

When Hanna and ernicka-Goetz each published their findings after the meeting in Santa Cruz, The Washington Post wrote that the advances put the possibility of a complete human synthetic embryo on the horizon. That nomenclature was unfortunate, as these arent synthetic at all, but rather entirely biological. (Thats why scientists prefer the term embryo models.) But they were spot on about the implications. And about the timing: reports of embryo models made from human stem cells hit newspapers exactly a year later, in the summer of 2023.

This is no incremental change and, despite the flawed press narrative, ernicka-Goetz and Hanna arent the only or even the most important players in the game. Other influential biologists are making huge strides too, though their names arent often in the press. Some have even argued that the new advances challenge the current legal definitions of the embryo, which prompts the question: how should we define an embryo? And what do we do when, as they certainly will, scientists definitions differ from the general publics? As embryo models become more sophisticated, how will we know when that clump of tissue in the dish becomes an embryo?

Ive studied embryos for more than 30 years, and while it doesnt often catch the publics attention, developmental biology is something society needs to understand. And dont we want to? Isnt it just another way of framing that ancient and universal question: How did I get here?

Human contemplation of embryonic development is nearly as old as writing. In the Old Testament story, Job asks of God: Didst thou not pour me out like milk and curdle me like cheese? Half a world away, the Buddha uses the same dairy-based metaphor in the Garbhavakrantisutra, a 1st-century scripture. Some of the earliest cultures in Southern Mexico left no writing, but they made statues of human fetuses. Anywhere you go in the ancient world, you find embryos.

In ancient Greece, as light began to show in the cracks that separate religion, philosophy and science, a remarkable treatise appeared. To modern eyes, On the Nature of the Child attributed to Hippocrates is bent on explaining human development, though it does so largely by describing the development of a hens egg. Actually, not an egg but 20 eggs, each of which the author exhorts us to open on successive days, so we can observe development over time: You will find everything as I say in so far as a bird can resemble a man.

Aristotle rejected preformation, and argued instead for a progressive development

That ancient appreciation of time is critical, for it frames the first key question in the history of developmental biology: does an embryo acquire its complexity piece by piece, somehow progressively assembling itself? Or is that new organism already present in the egg or sperm, preformed, as it were, and needing only to be spurred somehow to grow? Some readers will be familiar with the iconic image of preformation a tiny human curled up inside a sperm. Its late-17th-century printing underscores just how long we struggled to resolve these two poles of thought, progressive versus preformed.

Aristotle himself was the first to weigh in. Consulting farmers and fishermen with the same enthusiasm with which he debated scholars, the philosopher described everything from the live births of dolphins to the size of elephant embryos. He compared the embryos of chickens, fish, insects and, yes, humans. He rejected preformation: our senses tell us plainly that this does not happen. He argued instead for a progressive development, and while it took 2,000 years to resolve, he was exactly right.

Just how this progression happens remains the core question of developmental biology. And as we begin to explore the truly uncharted morality of embryo models and their progressive development, what strikes me most about the concept is how neatly it parallels ancient thoughts about inchoate humanity.

In the modern debate over abortion, the doctrine that life begins at conception is now so constantly repeated that its often assumed to have an ancient, perhaps even scriptural origin. It does not.

In fact, in Catholic canon law, the doctrine dates precisely to 12 October 1869, when Pope Pius IX declared excommunication as the penalty for anyone involved in obtaining any abortion. For the nearly 2,000 years that had gone before, however, many Christian thinkers held the embryo to acquire its humanity only gradually. This concept, linked to the animation or ensoulment of the embryo, arose in laws first set down more than 3,000 years ago that imposed increasingly harsher penalties for causing the loss of a pregnancy as it progressed.

The idea was widely, if not uniformly, adopted by early Christian jurists. St Augustine held this view; St Basil was opposed. None wielded greater influence than St Thomas Aquinas, whose 13th-century rendering of Aristotles progressive acquisition of humanity in utero became a prominent, perhaps dominant concept in Western Christianity. It surfaced everywhere from Dantes poetry to Celtic law for 500 years.

The embryos of scientists are not the embryos of the public, or the Church

Of course, saints werent the only ones thinking about embryos. Leonardo da Vinci drew several in the 16th century, one now famous for its inaccuracy. When the modern university was being developed in a 16th-century Italy roiled by Protestant Reformation and Catholic Counter-Reformation, scholars on both sides cracked open chicken eggs to study embryos. A century later, a less divided group (all Royalists in the English civil wars) still hotly debated the chick embryo. And when modern science began to emerge in the 17th century, its founding figures had more than a passing interest in the embryo.

By the 19th century, the new scientists had reached consensus. The concept of progressive embryonic development of animal embryos was established once and for all. But then as now, the embryos of scientists are not the embryos of the public, or the Church. In an odd synchronicity, science and Church staked out opposite views at essentially the same time.

A mere 23 days separated Pope Piuss decision and an important lecture by the embryologist Wilhelm His. Propounding a new vision for understanding progressive development of the embryo, His would go on to publish The Form of Our Body and the Physiological Problem of Its Development (1874). It was despite the possessive in the title a thoroughgoing discussion of chicken embryos. But His said exactly what he meant. Soon after, he would combine lessons learned from chickens with a network of physicians, and become the first to comprehensively define, cogently describe, and accurately display the progressive development of human embryos.

Selections from the normal table of human development: the embryologist Wilhelm His et al produced the scientific conception of the human embryo in the 1870s using careful staging and illustration. From Anatomie menschlicher Embryonen (1880-85). Courtesy the Wellcome Library

As the Cambridge historian Nick Hopwood put it, His and others produced the very concept of the embryo as we know it. And, while embryos certainly exist as tangible, biological entities, this concept is so central to the work of developmental biologists that we rarely notice it. Were also slow to consider how others in society relate to it. And thats important, because, in the 20th century, the concept of the embryo changed radically yet again.

By the time the famous double helix structure of DNA was discovered in the early 1950s, fruit flies like Lehmanns had taught us that genes direct the inheritance of traits from one generation to the next; sea urchins showed us that genes reside on chromosomes in the cell nucleus; and bacteria and viruses revealed that genes were made of DNA. But the relationship between our genes and our development was still mostly a black box. When we first peeked in, it wasnt through the ascendant disciplines of genetics and biochemistry, but a more hands-on approach: transplantation. Not of organs, but of cellular bits.

In Nobel Prize-winning work, the British developmental biologist John Gurdon showed that if he destroyed the gene-containing nucleus of a one-cell frog embryo, normal development could be restored by transplanting the nucleus of some other cell. Fascinatingly, any cell nucleus might do the job, suggesting the tools needed to guide development of an entire organism are present in each and every one of its cells.

But there was a catch. Donor nuclei from early embryonic cells were far better at restoring development than those taken from later embryos. Such decreasing potency over time was a crucial revelation for understanding progressive development. The concept has its apotheosis in the British developmental biologist Conrad Waddingtons landscape, an iconic image depicting an early embryonic cell as a marble set to roll down a branching network of increasingly deep valleys. At the top, the marble might still roll into any number of valleys, but its inventory of potential shrinks with its descent. It cant roll back uphill.

Waddingtons landscape: in the iconic metaphor for progressive development, the marble represents a cell in an embryo; as the embryo develops, the cell rolls downhill. At the first decision point, the cell might choose one of two valleys, thus becoming one of two very general cell types, for example mesoderm or ectoderm. At the next branch, the cell will become one of two very specific cell types, and so on. From The Strategy of the Genes by C H Waddington (1957) George Allen & Unwin (London)

If the marble rolls down the valley biologists call mesoderm, it might roll further into clefts such as muscle or blood. But its cut off from the valleys of skin and brain, what we call ectoderm. Becoming an embryo, then, is the collective navigation of an ever-branching decision-tree by a constantly multiplying population of cells. So its tempting to think that some notion of sufficient complexity, a far-enough journey down the valleys, might help us divine precisely when its an embryo, and when its a human.

Edwards had studied the possibility of IVF in mice, then sheep, cows, pigs, monkeys

But, again, theres a catch. While most cells in the early embryo rush down the valleys, a privileged few will linger at the top of the landscape. Described first in rabbits by Waddingtons own pupil at the University of Edinburgh, Robert Edwards, we now call these embryonic stem cells, and by the turn of the 21st century they were as much a part of politics as of biology. But when first described in the early 1960s, neither Edwards nor anyone else capitalised on their potential. And, anyway, Edwards was busy with another project. The era of test-tube babies was upon us.

Late in 1977, Edwards wrote a note to one of his patients, Lesley Brown: [Y]ou might be in early pregnancy. So please take things quietly no skiing. Some weeks earlier, shed had one of her eggs laparoscopically inserted into her uterus; it had been fertilised in vitro with her husband Johns sperm. In 1978, Louise Brown, the first child conceived by IVF, was born.

The feat capped more than a decade of hard work. Edwards had studied the possibility of IVF in mice, then sheep, cows, pigs, monkeys. Eventually, human oocytes removed in a hospital in Oldham made the four-hour journey to Edwards lab in Cambridge. And, there, he was the first to glimpse the moment when the Church says life begins. Coming precisely a century after Pius IXs decision, his co-authored 1969 paper describing human fertilisation for the first time had been a watershed moment in the 3,000-year history of embryology. But it was also, well, just developmental biology: Penetration of spermatozoa into the perivitelline space was first seen in eggs examined 7-7.25 h after insemination.

The human embryo had become one of the scientists embryos and, in another remarkable synchronicity, the very same embryo had also exploded into the public consciousness. Not in a scientific journal, but in a glossy magazine.

The cover of Life magazine from 30 April 1965 is a startling artefact, filled by a colour photo of an 18-week human fetus. The essay inside produced the concept of human embryos for the public just as His did for scientists during the previous century. Read by millions, it forever changed our idea of what a living, developing, growing human embryo looks like. But it was just that, an idea. In reality, the fetus on the cover of Life magazine was dead.

Drama of life before birth: cover of Life magazine, 30 April 1965. Courtesy Photo12/Getty

The essay was filled with similarly lifelike photos, all but one of which actually show dead or dying embryos and fetuses, the results of either miscarriage or termination. This fact was ignored by anti-abortion activists who made these images ubiquitous; it suited their needs. Depicting these surgically removed embryos as somehow both alive and autonomous made it easy to ignore the mother, whose adult body is so essential for the embryos growth and development, and who is so at risk. Volumes have now been written about these images and their role in the US abortion debate.

Just 77 seconds of airtime for the entire essence of development as science knows it

But what strikes the developmental biologist in me is just how accurately the essay conveyed progressive human development. We see the fertilised egg, and we follow the changes of the largely unformed embryo at three, four, and six weeks. Only at eight weeks do we finally see its gradual transition to the more obviously human fetus.

Sadly, this narrative was lost when the images were packaged into a documentary film in 1982. Influenced perhaps by Louise Browns birth and that of the modern fertility industry The Miracle of Life runs for an hour, yet the first 41 minutes show only egg or sperm. Mostly sperm. By 48 minutes, weve seen fertilisation, but the embryo is still just a round clump, perhaps eight cells. Its only at 48:33 that we catch our first glimpse of the real action of development, the progressive emergence of form. And by 49:50, its all over. Suddenly, there are tiny fingers, eyes looking right at us. Just 77 seconds of airtime for the entire essence of development as science knows it. Shown on the BBC, PBS and outlets around the world, the award-winning documentary easily eclipsed the Life essay. The public human embryo had truly arrived and, besides a few seconds of embryonic development shown on fast-forward, it was a fully developed fetus.

Not long after, the joyful presentations of sonograms, with their beating heart or their shadow of a face, became a core ritual of pregnancy. But these very public fetuses are wildly at odds with the biological reality of embryos, the majority of which abort spontaneously at an early stage; this led an academic theologian to muse that, if life began at fertilisation, then it would appear that heaven is mostly populated by them [embryos] rather than by people who had actually been born.

Over a scant two decades, what we now call the human embryo went from a largely intangible entity to something scientists could routinely manipulate and the public thought they understood. As the 1980s dawned, august bodies of scientists, religious leaders, lawyers and philosophers unanimously settled on a progressive view of development.

They concluded that human embryos should be kept alive in vitro only for the most important, highly regulated reproductive or research purposes. Moreover, they must be kept alive only for 14 days. This time point, chosen on the advice of a developmental biologist, was at once appropriate and arbitrary. On the one hand, it marks the onset of a process called gastrulation, by which the embryo leaves behind its early ball-like form and begins to build an elongate body. Its also the last point at which twinning can occur, and so makes the embryo truly singular and unique. But gastrulation takes some time and embryos are variable. Only a true expert could glean the distinction between embryos at 13, 14 and 15 days. Yet, as any lawyer will tell you, laws (and even guidelines) must be specific to be meaningful, and The 14-Day Rule was both.

Their genesis in unused embryos of IVF patients and therapeutic terminations sparked a culture war

Those were exciting times for animal embryology too, given the Nobel Prize-winning work of Christiane Nsslein-Volhard, Eric Wieschaus and Edward Lewis. They showed that the entire zoo of animals wed studied for decades, centuries, even millennia all use a shockingly similar genetic toolkit to guide development. When chick embryos were first compared with humans in ancient Greece, it was exactly right.

A single genetic toolkit for development: flies with mutations in what scientists call homeobox genes display duplicated wings (above photo courtesy Nicolas Gompel). Mice with mutations in these genes display duplicated ribs (below, Daniel C McIntyre et al, Development [2007])

Around the same time, the biologist Gail Martin at the University of California, San Francisco made good on Edwardss abandoned project. Coining the term embryonic stem cells, she and her colleagues learned how to get these cells from mice, keep them alive in culture dishes, and make them differentiate into cartilage or even neuron-like cells. When the same was done with human embryonic stem cells in 1998, their genesis in unused embryos of IVF patients and therapeutic terminations sparked a culture war. But neither politics nor the resulting welter of regulations dented enthusiasm for their tremendous promise both real and as imagined by charlatans.

By tinkering with the genetic toolkit that developmental biologists discovered in animal embryos, the new stem cell scientists coaxed their wards down Waddington valleys of their choosing. Their arcane recipes recall ancient alchemy, but the ecosystems they conjured in little plastic dishes were entirely real. First, they made single human cell types, neurons, muscle, blood. Not long after, they devised functional, three-dimensional tissues, first eyes in a dish, then miniguts and minibrains, an array we collectively call organoids.

It was only a matter of time before the idea arose that we might construct whole embryos out of stem cells. Guided by a desire to understand human development (and in some cases, surely, by at least a little hubris), progress came with unnerving speed.

At the 2022 meeting on developmental biology in Santa Cruz, I was giddy, mesmerised by the confluence of developmental and stem cell biology. Lehmanns lecture on flies and my own about frogs joined others about fish and worms. There was even a lecture about jerboas, a strange hopping rodent from Mongolia. One talk really blew my mind: unable to study rhinoceros embryos, for obvious reasons, one group has convinced their stem cells to make rhino embryo models of a sort.

My joy, however, soon bled into dismay when The Washington Post, describing the mouse embryo models developed by Hanna and by ernicka-Goetz, noted rightly that human models were all but inevitable. Given that years of debate went into the 14-Day Rule in the 1980s, we might have expected that move to be cautious and deliberate. It wasnt. At a conference in Boston in June 2023, ernicka-Goetz claimed that we can create human embryo-like models by the reprogramming of [embryonic stem] cells, a statement The Guardian blasted out to the public the following day without any back-up from the peer review. Once the peer-reviewed paper appeared, it became clear that ernicka-Goetzs initial claim had been overstated. Hannas group reported more impressive human embryo models soon after, but these couldnt justify the media commentary either.

The work, while vetted and approved by the appropriate ethics committees, is a far cry from helping us frame the ethical considerations these embryo models will raise. Indeed, while the current embryo models cannot develop into a viable fetus, it sure looks like we will get to that point. And it doesnt help that the International Society for Stem Cell Research in 2021 relaxed the 14-Day Rule for research with human embryos made the old-fashioned way. Unlike the careful deliberation with stakeholders in the 1980s, the new decision was reached without public engagement. I think the entire field is obligated to bring more people into the conversation and to better articulate why the work is necessary why, in fact, we must make human embryos from scratch.

This science has always been a proxy, however imperfect, for understanding how our own bodies come to be

Its troubling, too, that the scientists getting the most attention dont always use their cachet to communicate the nuance, both ethical and biological. Instead, its left to others. Alfonso Martinez Arias, Nicolas Rivron and Kathy Niakan, for example, are among those who have provided thoughtful commentary on the complexities in scientific journals. And, while ernicka-Goetz in June 2023 told The New York Times that we do it to save lives, not create it, the medical applications are not at all clear to me. Exactly how will these models save lives? And exactly how do they compare with alternative solutions to the problem? Without such details, how can we weigh whats to be gained against our ethical and moral obligations?

By contrast, the decades of research with old-fashioned human embryos, all conducted within the confines of the 14-Day Rule, brought us a remarkably safe and effective fertility industry, as well as important advances in genetic diagnosis and prevention of diseases and birth defects. These advances continue, with benefits that are clear.

Weve pondered embryos for thousands of years, in part because they spark our inherent wonder; theirs is the ultimate emergent property. Across that long arc, its usually been animal embryos under our microscopes, organisms that assemble themselves just like we do but whose development we have fewer qualms about interrupting for the sake of knowledge. Like any basic science, animal embryos provide a glimpse of what is possible in this world, Lehmann writes. But this science has always been a proxy, however imperfect, for understanding how our own bodies come to be. And, quite suddenly now, we seem to have the tools and the appetite to get far more than just a glimpse at the human embryo.

Martinez Arias recently told me that when you put the word human there, you are talking to the whole of society. Its worth recalling, then, that this conversation is also thousands of years old. And history tells us that our collective decisions on issues of the human embryo will ultimately be influenced by both science and faith.

Science can tell us how the human embryo develops, and it is an undisputed certainty that embryos develop progressively, building complexity and identity only over time. But there is no scientific consensus on when during that progression life begins. Likewise, there is no consensus among faiths on when life begins. Certain Christian faiths now hold that life begins at conception, and these have an outsized influence. Yet, even within Christianity, that view is a recent stance, and one that reversed centuries of thought. Other Western religious traditions dont share Christianitys ambiguity. Cleaving to the ancient gradualist view of development, Islamic tradition generally holds the embryo to become human 120 days after fertilisation, though some use the 40-day mark; in most Jewish traditions, it happens only at birth.

We are 3,000 years deep in the adventure called developmental biology, yet the embryo remains in many ways just as mysterious as ever. As we enter a new era of explicitly human developmental biology, we should approach it with all the grace and humility we possibly can.

More here:
After 3,000 years of science, the embryo is very different - Aeon